Morgan E, Donaldson M H, Meadows A T
Cancer. 1977 Sep;40(3):1005-9. doi: 10.1002/1097-0142(197709)40:3<1005::aid-cncr2820400307>3.0.co;2-1.
The efficacy of intrathecal (IT) maintenance chemotherapy following central nervous system (CNS) leukemia was demonstrated in a retrospective study of 77 such episodes. The median durations of CNS and bone marrow (BM) remissions were significantly longer for the 41 maintained episodes (10+ and 9.5 months, respectively) compared with the 36 unmaintained episodes (4 and 2 months, respectively). Patients were comparable in each of these two groups. For those patients receiving maintenance therapy, there appeared to be an advantage in using four or more doses of IT medications for treatment of CNS leukemia, regardless of the number of doses necessary to clear the cerebrospinal fluid (CSF).
在一项对77例此类病例的回顾性研究中，证实了鞘内（IT）维持化疗对中枢神经系统（CNS）白血病的疗效。41例维持治疗的病例中枢神经系统和骨髓（BM）缓解的中位持续时间（分别为10多个月和9.5个月）明显长于36例未维持治疗的病例（分别为4个月和2个月）。这两组中的患者在各方面具有可比性。对于那些接受维持治疗的患者，无论清除脑脊液（CSF）所需的剂量数是多少，使用四剂或更多剂量的IT药物治疗CNS白血病似乎具有优势。
